Skip to main content

Refractory Tumor clinical trials at UCSD

1 in progress, 0 open to eligible people

Showing trials for
  • STI-6643 in Subjects With Advanced Solid Tumors

    Sorry, not currently recruiting here

    This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.

    San Diego, California and other locations

Last updated: